Effects of Turmeric on Homocysteine and Fetuin-A in Patients With Nonalcoholic Fatty Liver Disease: A Randomized Double-Blind Placebo-Controlled Study

被引:10
|
作者
Ghaffari, Aida [1 ]
Rafraf, Maryam [2 ]
Navekar, Roya [3 ]
Sepehri, Bita [4 ]
Asghari-Jafarabadi, Mohammad [5 ,6 ]
Ghavami, Seyyed-Mostafa [7 ]
Manafi, Nahid [8 ]
机构
[1] Tabriz Univ Med Sci, Fac Nutr & Food Sci, Students Res Comm, Tabriz, Iran
[2] Tabriz Univ Med Sci, Fac Nutr & Food Sci, Dept Community Nutr, Tabriz, Iran
[3] Tabriz Univ Med Sci, Student Res Comm, Tabriz, Iran
[4] Tabriz Univ Med Sci, Fac Med, Dept Gastroenterol & Hepatol, Tabriz, Iran
[5] Tabriz Univ Med Sci, Rd Traff Injury Res Ctr, Tabriz, Iran
[6] Tabriz Univ Med Sci, Fac Hlth, Dept Stat & Epidemiol, Tabriz, Iran
[7] Tabriz Univ Med Sci, Fac Paramed, Dept Radiol, Tabriz, Iran
[8] Sanjesh Lab, Tehran, Iran
关键词
Turmeric; Homocysteine; Fetuin-A; Nonalcoholic Fatty Liver; INSULIN-RESISTANCE; SERUM FETUIN; ENDOTHELIAL DYSFUNCTION; METABOLIC SYNDROME; CURCUMIN; PLASMA; RATS; ASSOCIATION; OBESITY; RISK;
D O I
10.5812/ircmj.43193
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Background: Elevated levels of homocysteine (Hcy) and fetuin-A are important risk factors for cardiovascular diseases in patients with a nonalcoholic fatty liver disease (NAFLD). There is limited evidence regarding the effects of turmeric on NAFLD. Objectives: This study aimed at investigating the effects of turmeric supplementation on serum levels of Hcy and fetuin-A in patients with NAFLD. Methods: In this double-blind, randomized, controlled clinical trial, 46 NAFLD patients (21 males and 25 females; age range, 20-60 years) with body mass index ranged 24.9 - 40 kg/m(2) were recruited from Sheikh-ol-Raees clinic in Tabriz City, Iran during Nov 2014May 2015. The participants were allocated into the two groups using the block randomization method. The intervention and control groups received 3g of turmeric (n = 23) and placebo (n = 23), daily for 12 weeks. Fasting blood samples were collected at baseline and at the end of the trial for biochemical analysis. Results: Turmeric supplementation significantly decreased serum levels of Hcy, compared with the placebo group at the end of the study (by 27.83%, P = 0.034). No significant difference was observed between the two groups in serum levels of fetuin-A after the intervention (P > 0.05). Serum levels of glucose, insulin and homeostasis model assessment for insulin resistance were declined significantly in the turmeric group (by 1.22%, 17.69% and 19.48%, P = 0.039, P = 0.013 and P = 0.001, respectively) compared to the placebo. Conclusions: Turmeric consumption had beneficial effects on serum Hcy levels andmaybe useful inmanagementof this risk factor in NAFLD patients.
引用
收藏
页数:6
相关论文
共 50 条
  • [1] A pilot study of the effects of chromium picolinate supplementation on serum fetuin-A, metabolic and inflammatory factors in patients with nonalcoholic fatty liver disease: A double-blind, placebo-controlled trial
    Moradi, Fardin
    Kooshki, Fateme
    Nokhostin, Forough
    Khoshbaten, Manouchehr
    Bazyar, Hadi
    Gargari, Bahram Pourghassem
    JOURNAL OF TRACE ELEMENTS IN MEDICINE AND BIOLOGY, 2021, 63
  • [2] Ginger Supplementation in Nonalcoholic Fatty Liver Disease: A Randomized, Double-Blind, Placebo-Controlled Pilot Study
    Rahimlou, Mehran
    Yari, Zahra
    Hekmatdoost, Azita
    Alavian, Seyed Moayed
    Keshavarz, Seyed Ali
    HEPATITIS MONTHLY, 2016, 16 (01)
  • [3] Randomized, Double-blind, Placebo-controlled Study of a Multispecies Probiotic Mixture in Nonalcoholic Fatty Liver Disease
    Anh, Sang Bong
    Jun, Dae Won
    Kang, Bo-Kyeong
    Lim, Jong Hyun
    Lim, Sanghyun
    Chung, Myung-Jun
    SCIENTIFIC REPORTS, 2019, 9 (1)
  • [4] Synbiotic supplementation in nonalcoholic fatty liver disease: a randomized, double-blind, placebo-controlled pilot study
    Eslamparast, Tannaz
    Poustchi, Hossein
    Zamani, Farhad
    Sharafkhah, Maryam
    Malekzadeh, Reza
    Hekmatdoost, Azita
    AMERICAN JOURNAL OF CLINICAL NUTRITION, 2014, 99 (03): : 535 - 542
  • [5] Randomized, Double-blind, Placebo-controlled Study of a Multispecies Probiotic Mixture in Nonalcoholic Fatty Liver Disease
    Sang Bong Ahn
    Dae Won Jun
    Bo-Kyeong Kang
    Jong Hyun Lim
    Sanghyun Lim
    Myung-Jun Chung
    Scientific Reports, 9
  • [6] A double-blind randomized placebo-controlled trial of orlistat for the treatment of nonalcoholic fatty liver disease
    Zelber-Sagi, Shira
    Kessler, Ada
    Brazowsky, Eli
    Webb, Muriel
    Lurie, Yoav
    Santo, Moshe
    Leshno, Moshe
    Blendis, Laurence
    Halpern, Zamir
    Oren, Ran
    CLINICAL GASTROENTEROLOGY AND HEPATOLOGY, 2006, 4 (05) : 639 - 644
  • [7] Resmetirom for nonalcoholic fatty liver disease: a randomized, double-blind, placebo-controlled phase 3 trial
    Harrison, Stephen A.
    Taub, Rebecca
    Neff, Guy W.
    Lucas, K. Jean
    Labriola, Dominic
    Moussa, Sam E.
    Alkhouri, Naim
    Bashir, Mustafa R.
    NATURE MEDICINE, 2023, 29 (11) : 2919 - 2928
  • [8] Resmetirom for nonalcoholic fatty liver disease: a randomized, double-blind, placebo-controlled phase 3 trial
    Stephen A. Harrison
    Rebecca Taub
    Guy W. Neff
    K. Jean Lucas
    Dominic Labriola
    Sam E. Moussa
    Naim Alkhouri
    Mustafa R. Bashir
    Nature Medicine, 2023, 29 : 2919 - 2928
  • [9] Effect of Turmeric Supplementation on Blood Pressure and Serum Levels of Sirtuin 1 and Adiponectin in Patients with Nonalcoholic Fatty Liver Disease: A Double-Blind, Randomized, Placebo-Controlled Trial
    Kalhori, Ali
    Rafraf, Maryam
    Navekar, Roya
    Ghaffari, Aida
    Jafarabadi, Mohammad Asghari
    PREVENTIVE NUTRITION AND FOOD SCIENCE, 2022, 27 (01) : 37 - 44
  • [10] Pentoxifylline for the treatment of nonalcoholic fatty liver disease: a meta-analysis of randomized double-blind, placebo-controlled studies
    Zeng, Tao
    Zhang, Cui-Li
    Zhao, Xiu-Lan
    Xie, Ke-Qin
    EUROPEAN JOURNAL OF GASTROENTEROLOGY & HEPATOLOGY, 2014, 26 (06) : 646 - 653